US Broker Ratings

Immunome, Inc. (IMNM) Investor Outlook: Strong Buy Ratings Signal Potential 109% Upside

Immunome, Inc. (NASDAQ: IMNM), a clinical-stage biotechnology company, is capturing investor attention with its promising pipeline in targeted cancer therapies. Based in Bothell, Washington, Immunome focuses on innovative treatments for..

Evolus, Inc. (EOLS) Stock Analysis: Unveiling a Potential 201% Upside with Analyst Confidence

Evolus, Inc. (NASDAQ: EOLS), a key player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry, has been capturing the attention of investors with its promising..

Replimune Group, Inc. (REPL): Investor Outlook on Emerging Biotech with Oncolytic Immunotherapy Potential

Replimune Group, Inc. (NASDAQ: REPL) is capturing attention in the biotech sector with its innovative approach to treating cancer through oncolytic immunotherapies. Headquartered in Woburn, Massachusetts, this clinical-stage company is..

Personalis, Inc. (PSNL) Stock Analysis: Navigating Growth Challenges Amidst Promising Advances in Cancer Genomics

Investors with an eye on the healthcare sector, particularly in the cutting-edge realm of cancer diagnostics and research, are likely familiar with Personalis, Inc. (NASDAQ: PSNL). This Fremont, California-based company..

CureVac N.V. (CVAC) Stock Analysis: Navigating a Biotech Pioneer with a Strong Return on Equity

CureVac N.V. (NASDAQ: CVAC) is a biopharmaceutical company at the forefront of mRNA-based therapeutic development. Based in Tübingen, Germany, CureVac has carved a niche in the dynamic biotechnology industry, focusing..

Owens & Minor, Inc. (OMI)

⚠️ No article content returned.

..

Opthea Limited (OPT) Stock Analysis: Navigating the Biotech Waters with Potential Downside

Opthea Limited (NASDAQ: OPT), a crucial player in the biotechnology sector, is making waves with its innovative approach to treating serious eye conditions such as wet age-related macular degeneration (Wet..

Pharvaris N.V. (PHVS) Stock Analysis: Unpacking a Potential 46% Upside Amidst Biotech Innovations

Pharvaris N.V. (PHVS), a prominent player in the biotechnology sector, is capturing investor attention with its innovative approach to tackling rare diseases. Headquartered in Zug, Switzerland, this late-stage biopharmaceutical company..

Auna SA (AUNA) Stock Analysis: Exploring a Potential 79% Upside in the Healthcare Sector

Auna SA (AUNA), a prominent player in the healthcare sector, operates a network of hospitals and clinics across Mexico, Peru, and Colombia. With its headquarters in Luxembourg, this medical care..

AnaptysBio, Inc. (ANAB) Stock Analysis: Biotechnology Innovator with a 65% Potential Upside

AnaptysBio, Inc. (NASDAQ: ANAB) is capturing the attention of investors with a compelling narrative of innovation in the healthcare sector, specifically in biotechnology. Based in San Diego, California, this clinical-stage..

iRadimed Corporation (IRMD) Stock Analysis: A Healthcare Innovator with a 5.51% Upside Potential

iRadimed Corporation (NASDAQ: IRMD) stands out as a niche player in the healthcare sector, specializing in MRI-compatible medical devices. With its roots firmly planted in the United States and operational..

Amylyx Pharmaceuticals (AMLX) Investor Outlook: Evaluating the 13.81% Upside Potential

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the biotechnology sector, is capturing investor attention with its focus on developing innovative treatments for neurodegenerative diseases and endocrine disorders. With..

CorMedix Inc. (CRMD) Stock Analysis: A Promising Upside with 85.52% Growth Potential

CorMedix Inc. (NASDAQ: CRMD) is making waves in the biopharmaceutical sector, capturing investor attention with its significant growth potential. With a market capitalization of $862.55 million, this healthcare-focused company is..

Ginkgo Bioworks (DNA) Stock Analysis: Navigating Challenges with Biotechnology Innovations

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) stands as a notable player in the biotechnology sector, with its innovative approach to cell programming. Headquartered in Boston, Massachusetts, Ginkgo Bioworks is at..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Navigating Market Dynamics with a 38.60% Revenue Growth

Phibro Animal Health Corporation (NASDAQ: PAHC) stands as a formidable player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With a market capitalization of $1.58..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Unlocking a 149% Potential Upside in Rare Disease Treatment

Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a leader in the biotechnology sector, is making waves with its innovative approach to treating rare diseases. With a market capitalization of $522.62 million, this..

Community Health Systems, Inc. (CYH) Stock Analysis: Navigating a 16% Potential Upside

Community Health Systems, Inc. (NYSE: CYH), a prominent player in the U.S. healthcare sector, operates a network of general acute care hospitals. Headquartered in Franklin, Tennessee, the company offers a..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Unveiling a Potential 10.63% Upside in the Healthcare Sector

Fulgent Genetics, Inc. (FLGT), a prominent player in the Healthcare sector, particularly in Diagnostics & Research, offers an intriguing investment proposition with a potential upside of 10.63% according to current..

AxoGen, Inc. (AXGN) Stock Analysis: Exploring a 38% Potential Upside in the Peripheral Nerve Repair Market

AxoGen, Inc. (NASDAQ: AXGN) stands out in the healthcare sector, specifically within the medical devices industry, by focusing on the niche market of peripheral nerve regeneration and repair. With a..

Definitive Healthcare Corp. (DH) Stock Analysis: Exploring a 36% Potential Upside Amidst Market Volatility

Definitive Healthcare Corp. (NASDAQ: DH) stands at a critical juncture as it aims to navigate the complexities of the healthcare information services industry. With a modest market capitalization of $346.61..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds